Gland Pharma Q1 FY26 Earnings Results: Profit Surges 50%, Cenexi Turns EBITDA Positive

Gland Pharma posted a solid performance in Q1FY26, reporting a 50% YoY rise in profit after tax (PAT) to ₹2,155 million. Revenue grew 7% YoY to ₹15,056 million. The company credited the strong performance to improved results in its core business and a turnaround at its European subsidiary, Cenexi, which achieved EBITDA breakeven this quarter.

Gland Pharma Q1 FY26 Earnings: Financial Highlights (Consolidated)

• Revenue: ₹15,056 Million, up 7% YoY and 6% QoQ
• EBITDA: ₹3,678 Million, up 39% YoY
• Adjusted EBITDA Margin: 25%, up 589 basis points
• PAT: ₹2,155 Million, up 50% YoY and 16% QoQ
• PAT Margin: Rose 405 bps YoY to 14%

Market-Wise Performance

• USA: ₹7,443 Mn (↓2% YoY)
• Europe: ₹3,302 Mn (↑29% YoY)
• Canada, Australia & NZ: ₹739 Mn (↑65% YoY)
• India: ₹594 Mn (↑13% YoY)
• Rest of World: ₹2,978 Mn (↑5% YoY)

Base Business (Gland) Performance

• Revenue: ₹10,409 Mn (↑3% YoY)
• EBITDA Margin: 35%, up from 29%
• PAT: ₹2,692 Mn (↑20% YoY)
• USA sales declined 5%, but other core markets like Europe and Australia saw significant growth

Operational Highlights

• R&D Expenses: ₹460 Million (4.4% of revenue)
• New Launches: 12 molecules, including complex injectables
• ANDA Filings: 1 filed, 9 approved in the US
• RTU Bags: 1 filed this quarter, total filings now 20, with 14 approvals
• Co-development: 15 products in pipeline; commercialisation expected by FY28

About Gland Pharma

Founded in 1978 in Hyderabad, Gland Pharma is one of India's leading injectable drug manufacturers, with operations in over 60 countries. The company focuses on B2B partnerships and specialises in sterile injectables for regulated markets.

Read More: Dividends & Bonus Issue This Week (August 4–8, 2025): Paras Defence, Nestle, Coal India, and More.

Gland Pharma Share Price Movement

As of 11:55 am IST on August 6, 2025, Gland Pharma share price (NSE: GLAND) was trading at ₹1,985.40, up by ₹20.70 or 1.05%. The stock opened at ₹2,020.20 and touched an intraday high of ₹2,089.40 and a low of ₹1,972.20. Its 52-week high is ₹2,220.95, while the 52-week low is ₹1,277.80. The quarterly dividend amount declared by the company is ₹4.52 per share.

Conclusion

Gland Pharma delivered a strong Q1FY26 performance with improved margins, record profitability, and steady expansion across global markets. Cenexi’s EBITDA breakeven and robust product pipeline position the company for sustained growth in the coming quarters.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.